Derya KOCAKAYA, Güzide Nevsun İNANÇ, Rafi Haner DİRESKENELİ, Fatma ALİBAZ ÖNER, Ümmügülsüm GAZEL, İrem HİCRET TOPÇU, Hakan ÖMER KARATAŞ, Murat KARABACAK, Mehmet Pamir ATAGÜNDÜZ

Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature

Background/aim: Tumor necrosis factor-alfa (TNF-a) antagonists are extensively utilized in the treatment of inflammatory rheumatic diseases and also shown to be effective in Behçet’s disease (BD) patients with major organ involvement. In this study, we aimed to reevaluate the incidence of tuberculosis (TB) infection after anti-TNFa treatments and to reveal the risk of TB in BD. Methods: Data of patients who received anti-TNFa treatment between 2005 and 2018 were assessed retrospectively. Demographic features, TNF-a antagonist type/treatment time, tuberculosis skin test (TST) and QuantiFERON results, isoniazid prophylaxis status, and concomitant corticosteroid (CS) treatments were collected. Results: A total of 1277 (male/female = 597/680; median age = 49 years) patients were treated with TNF-a antagonist for a median of 33 months (Q1:12, Q3:62). Thirteen (1%) patients developed TB during the follow-up period. Within 13 TB-positive patients, 7 of them had pulmonary, and 7 had extrapulmonary TB. Although, the median time of (month) TNF-a antagonist treatment was higher in TB-positive patients than negative ones, the difference was not statistically significant (48 and 33 months, respectively, p = 0.47). Similarly, TB-positive patients were treated with CSs more than TB-negative patients (80% vs. 60%). Time from the initiation of TNF-a antagonist treatment to the diagnosis of TB had a median of 40 months (Q1-Q3: 22-56). There was a statistically significant increase of TB development in BD patients than non-BD patients after TNF-a antagonists (7.5% vs. 0.8%, respectively, p = 0.007). When we combined our patients with the other series from Turkey, among 12928 patients who received TNF-a antagonists, TB was positive in 12 (3.9%) of 305 BD patients compared to 112 (0.9%) of 12623 non-BD patients (p < 0.00001). Conclusion: Our results suggest a higher frequency of TB infections in BD patients with TNF-a antagonists. As biologic agents are increasingly used for major organ involvement in current practice for BD, screening mechanisms should be carefully implemented.Key words: Behçet’s disease, TNF-a antagonists, tuberculosis

PDF

___

1. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Annals of the Rheumatic Disease 2018; 77 (6): 808-818. doi: 10.1136/annrheumdis-2018-213225
2. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under antiTNF-alpha therapy. Rheumatology (Oxford) 2003; 42 (5): 617- 621.
3. Kisacik B, Pamuk ON, Onat AM, Erer SB, Hatemi G et al. Characteristics Predicting tuberculosis risk under tumor necrosis factor-alpha inhibitors: report from a large multicenter cohort with high background prevalence. The Journal of Rheumatology 2016; 43 (3): 524-539. doi: 10.3899/ jrheum.150177
4. Direskeneli H, Mumcu G. A possible decline in the incidence and severity of Behçet’s disease: implications for an infectious etiology and oral health. Clinical and Experimental Rheumatology 2010; 28 (4 Suppl 60): 86-90. PMID: 20868578
5. Pehlivan M, Kürtüncü M, Tüzün E, Shugaiv E, Mutlu M et al. The comparison of socio-economic conditions and personal hygiene habits of neuro-Behçet’s disease and multiple sclerosis patients. International Journal of Hygiene and Environmental Health 2011; 214 (4): 335-337. doi: 10.1016/j.ijheh.2011.04.001
6. Keser G DH, Akkoç N. Rheumatology Research and Education Foundation’s Consensus Report on using TNF-α inhibitors 2005.
7. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Rheumatology 2001; 45 (1): 101-106. PMID: 11308054
8. Stenger S. Immunological control of tuberculosis: role of tumour necrosis factor and more. Annals of the Rheumatic Disease 2005; 64 Suppl 4: 24-28. doi: 10.1136/ard.2005.042531
9. Winthrop KL, Baxter R, Liu L, Varley CD, Curtis JR et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Annals of the Rheumatic Disease 2013; 72 (1): 37-42. doi: 10.1136/annrheumdis-2011-200690
10. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheumatology 2003; 48 (8): 2122-2127. doi: 10.1002/art.11137
11. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the Rheumatic Disease 2010; 69 (3): 522-528. doi: 10.1136/ ard.2009.118935
12. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheumatology 2009; 60 (7): 1884-1894. doi: 10.1002/art.24632
13. Cagatay T, Bingol Z, Kiyan E, Yegin Z, Okumus G et al. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk. The Clinical Respiratory Journal 2018; 12 (4): 1668-1675. doi: 10.1111/crj.12726
14. Borekci S, Atahan E, Demir Yilmaz D, Mazican N, Duman B et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-alpha treatment. Respiration 2015; 90 (3): 191-198. doi: 10.1159/000434684
15. Iliopoulos A, Kedikoglou S, Laxanis S, Kourouklis S, Katsaros E. A case of tuberculous meningoencephalitis in a patient with Behçet’s disease. Clinal Rheumatology 2006; 25 (1): 121-122. doi: 10.1007/s10067-005-1135-4
16. Yan Shen H-fM, Yan-li Yang, Jian-long Guan. Ulcerative intestinal tuberculosis case as a complication of treatment by infliximab for intestinal Behçet’s disease: a case report. Medicine (Baltimore) 2019; 98 (43): e17652. doi: 10.1097/ MD.0000000000017652
17. Freitas SM, Marques JS, Grilo A, Gomes R, Goncalves FM. Behçet’s disease and tuberculosis: a complex relationship. European Journal of Case Reports in Internal Medicine 2020; 7 (2): 001354. doi: 10.12890/2020_001354
18. Skvara H, Duschek N, Karlhofer F. De novo tuberculosis during infliximab therapy in a patient with Behçet disease. Journal of German Society of Dermatology 2009; 7 (7): 616- 619. doi: 10.1111/j.1610-0387.2009.07040.x
19. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G et al. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. The Lancet Infectious Disease 2018; 18 (3): 64-75. doi: 10.1016/S1473- 3099(17)30623-0
20. Sveinbjornsson G, Gudbjartsson DF, Halldorsson BV, Kristinsson KG, Gottfredsson M et al. HLA class II sequence variants influence tuberculosis risk in populations of European ancestry. Nature Genetics 2016; 48 (3): 318-322. doi: 10.1038/ ng.3498
21. Hwang CH, Khan S, Ende N, Mangura BT, Reichman LB et al. The HLA-A, -B, and -DR phenotypes and tuberculosis. The American Review of Respiratory Disease 1985; 132 (2): 382- 385. doi: 10.1164/arrd.1985.132.2.382
22. Hafez M, el-Salab S, el-Shennawy F, Bassiony MR. HLAantigens and tuberculosis in the Egyptian population. Tubercle 1985; 66 (1): 35-40. doi: 10.1016/0041-3879(85)90051-0
23. Hughes T, Coit P, Adler A, Yilmaz V, Aksu K et al. Identification of multiple independent susceptibility loci in the HLA region in Behçet’s disease. Nature Genetics 2013; 45 (3): 319-324. doi: 10.1038/ng.2551
24. McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. ‘MHC-I-opathy’-unified concept for spondyloarthritis and Behçet disease. Nature Reviews Rheumatology 2015; 11 (12): 731-740. doi: 10.1038/nrrheum.2015.147